These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35117106)

  • 1. The future is now: beyond first line systemic therapy in hepatocellular carcinoma.
    Nenu I; Breaban I; Pascalau S; Bora CN; Stefanescu H
    Transl Cancer Res; 2019 Apr; 8(Suppl 3):S261-S274. PubMed ID: 35117106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Therapy in Metastatic Hepatocellular Carcinoma.
    Elms D; Badami A; Dhanarajan A
    Curr Gastroenterol Rep; 2022 May; 24(5):65-71. PubMed ID: 35416635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
    Dipasquale A; Marinello A; Santoro A
    J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bibliometric study of immunotherapy for hepatocellular carcinoma.
    Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
    Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review.
    Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?
    Sparchez Z; Radu P; Bartos A; Nenu I; Craciun R; Mocan T; Horhat A; Spârchez M; Dufour JF
    World J Gastrointest Oncol; 2021 Dec; 13(12):1896-1918. PubMed ID: 35070032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
    Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TKIs in combination with immunotherapy for hepatocellular carcinoma.
    Stefanini B; Ielasi L; Chen R; Abbati C; Tonnini M; Tovoli F; Granito A
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):279-291. PubMed ID: 36794716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
    Boland P; Wu J
    Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.